諾誠健華(09969.HK)擬折讓8%配股 淨籌30.4億元
諾誠健華(09969.HK)公布,計劃配售2.11億股股份,佔擴大後股本14.04%,當中高瓴資本認購1.92億股、維梧資本認購1,889.5萬股;每股配售價為14.45元,較昨日收市價折讓8.08%。
公司預計所得款項淨額估計約為30.41億元,將用於在國內和國際地區擴大和加速正在進行和計劃進行的臨床試驗;留聘國內外人才,以增強集團在發現、臨床、業務開發和商業化領域的能力;擴大商業團隊,以確保奧布替尼及其後續產品的成功上市;擴大和加速內部發現階段項目,包括在研產品中的多個IND準備階段候選藥物;為任何潛在的外部協作和授權引進機會儲備資金;及用作營運資金和其他一般公司用途。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.